That's because it is already in the process of running the ongoing phase 3 LEVEL study and is set to begin the second phase 3 study soon in 2025. Both of these late-stage studies are using this ...

LAWRENCEVILLE, N.J., March 24, 2025 (GLOBE NEWSWIRE) -- IMUNON, Inc. (NASDAQ: IMNN), a clinical-stage company in Phase 3 development with its DNA-mediated immunotherapy, today announced that the U ...

Eli Lilly has met its goal of achieving semaglutide-like efficacy with an oral GLP-1 drug. The phase 3 study linked the oral GLP-1 drug orforglipron to similar reductions in blood glucose and body ...

Lilly plans to submit orforglipron for approval in weight management by the end of 2025, with a T2D application to follow in ...

Crypto chatter is hitting a new pitch in 2025. Between major protocol upgrades, surging on-chain activity, and surging ...

Enriqueta Felip, MD, PhD, discusses the design of the phase 3 3475A-D77 trial evaluating subcutaneous pembrolizumab in metastatic NSCLC. Enriqueta Felip, MD, PhD, the Universitat Autònoma de Barcelona ...

Data from the two phase 3 studies also showed that clinical decline was reduced in participants who had plasma p-tau181 reduction at 78 weeks, which Haeberlein said was a "meaningful" finding.

Australian-US biotech Opthea Ltd has reported disappointing phase 3 results with its lead drug for vision-robbing disease wet age-related macular degeneration (AMD), throwing its future into doubt.

Based on the phase 3 CABINET trial, the FDA approved Cabometyx for some patients with previously treated neuroendocrine tumors. The U.S. Food and Drug Administration (FDA) has approved Cabometyx ...

The phase 3 OVATION 3 trial will evaluate IMNN-001's efficacy and safety in advanced ovarian cancer patients, comparing it with standard chemotherapy. Phase 2 results demonstrated a 35% improvement in ...